• Home
  • About Us
    • About EZZ
    • Our Strategy
    • Our People
    • Corporate Directory
  • Our Brands
  • Investors
    • Investor Welcome
    • ASX Announcements
      • Annual Report
      • Results and Reports
      • Annual General Meeting
    • Corporate Governance
      • Board and Board Committees
      • Conducts and Ethics Policies and Procedures
      • Corporate Governance Statement
      • Other Governance Document
    • Investor Services
  • Shop
  • News
  • Contact
Skip to content
EZZ Life Sciences
  • Home
  • About Us
    • About EZZ
    • Our Strategy
    • Our People
    • Corporate Directory
  • Our Brands
  • Investors
    • Investor Welcome
    • ASX Announcements
      • Annual Report
      • Results and Reports
      • Annual General Meeting
    • Corporate Governance
      • Board and Board Committees
      • Conducts and Ethics Policies and Procedures
      • Corporate Governance Statement
      • Other Governance Document
    • Investor Services
  • Shop
  • News
  • Contact

Blog

EZZ Marks Transition to Genomic Health Following Exceptional FY21 Performance

by administratorNewsPosted on October 29, 2021January 26, 2025Comments are Disabled

EZZ Delivers Strong FY21 Operational Performance, Declares Dividend

by administratorNewsPosted on October 29, 2021January 26, 2025Comments are Disabled

EZZ Life Science Holdings (ASX: EZZ) Posts Strong Financial Results

by administratorNewsPosted on August 24, 2021January 26, 2025Comments are Disabled

FY21 4C Results & Investor Briefing

by administratorPresentationsPosted on August 23, 2021February 10, 2025Comments are Disabled

FY21 4C Results & Investor Briefing Details

by administratorPresentationsPosted on August 23, 2021January 26, 2025Comments are Disabled

EZZ Investor Presentation

by administratorPresentationsPosted on April 14, 2021February 10, 2025Comments are Disabled

ASX listing: ringing of the bell video

by administratorPresentationsPosted on March 8, 2021January 26, 2025Comments are Disabled

Ausbiz: EZZ Life Science debuts on the market

by administratorNewsPosted on March 3, 2021January 26, 2025Comments are Disabled

EZZ Life Science Holdings Limited to list on the ASX today following oversubscribed A$6m IPO

by administratorNewsPosted on March 3, 2021January 26, 2025Comments are Disabled

Gutenberg Sample Post

by administratorUncategorizedPosted on November 9, 2019January 26, 2025No Comments

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum is simply dummy text of the printing and typesetting industry. If you want to read, I might suggest a good book, perhaps Melville. That’s why they call it, the dummy copy. This, of course, is not the real copy for this …

Read more “Gutenberg Sample Post”

Posts pagination

1 … 6 7 8

Get in touch

Subscribe to email alerts

  • Facebook
  • X
  • LinkedIn

Quick Links

  • Home
  • About Us
  • Our Brands
  • Investors
  • Shop
  • News
  • Contact

Contacts

1/55-59, Parramatta Rd,
Lidcombe NSW 2141

ACN: 608 363 604

Info@ezzlife.com.au

www.ezzlife.com.au

Copyright © 2026 EZZ Life Sciences Inspiro Theme by WPZOOM

James Hudson

Director of Corporate Affairs, EZZ Life Science Holdings

James Hudson is the Director of Corporate Affairs at EZZ Life Science, where he oversees media relations, investor relations, and public affairs for the company.

Before joining EZZ, James was the Director of Corporate Affairs and Marketing at Alibaba Group for Australia and New Zealand. He has also served as the CEO of the Australia China Business Council's NSW branch, where he supported member companies in trade, investment, and business engagements with China. Additionally, he has held the role of China and East Asia Adviser at CSIRO, Australia’s national science research agency.

James has been appointed to various Advisory Board and Ambassador positions, including with the Asia Education Foundation, the China Australia Millennial Project, AsiaRecon, the Asian Football Cup, and Austrade’s Approved Destination Status Advisory Panel. He has also served as a non-executive director for organisations such as OneSky Australia and the Castlemaine State Festival.

Jay Stephenson

Company Secretary

Jay Stephenson has been involved in business development for over 35 years including approximately 29 years as Director, Chief Financial Officer and Company Secretary for various listed and unlisted entities in resources, manufacturing, information technology, health care, wine, hotels and property. Jay has been involved in business acquisitions, mergers, initial public offerings, capital raisings, business restructuring as well managing all areas of finance for companies.

Jay provides services in IPO/RTO management, Corporate Advisory, Company Administration, Accounting and Corporate Governance. On most engagements, Jay takes on the appointment of a statutory office holder, either as a Director, Company Secretary or Chief Financial Officer.

Jay holds a Master of Business Administration, is a Chartered Accountant, Fellow of Certified Practicing Accountants Australia, A Fellow of the Governance Institute of Australia, a member of Chartered Professional Accountants and Certified Management Accountants in Canada.

Anthony Guarna

Chief Financial Officer

With over 30 years of experience as a chartered accountant, Anthony Guarna has held positions at Deloitte, BDO, and Nexia, both domestically and internationally. He has provided financial leadership at organizations such as Energy Australia, the University of Sydney, Macquarie University, Tower Life, Electroboard Group, the Australian Institute of Higher Education, Austral Gold Limited (ASX: AGD), Aumake Limited (ASX: AUK), and Freedom Insurance Group Limited (ASX: FIG). Anthony also serves as a Non-Executive Director of the Sydney Institute of Traditional Chinese Medicine and is a member of the Advisory Board at Medigalaxy.

Hao (Lily) Huang

Independent Non-Executive Director

With more than 20 years in senior management within the banking industry, Lily Huang serves as Vice President in the investment partnerships division at Citi Group Australia. Her leadership was recognized in 2015 when she was named among the Top 10 Australian Chinese Entrepreneurs.

Ivan Oshry

Independent Non-Executive Director

Bringing over 30 years of legal practice experience both in Australia and internationally, Ivan Oshry specializes in corporate law. He has advised on numerous IPO transactions globally and is a sought-after speaker at various conferences, reflecting his deep industry knowledge.

Mark (Qizhou) Qin

Executive Director and Chief Executive Officer

An award-winning research analyst and accomplished entrepreneur, Mark Qin co-founded CE International, a multi-award-winning marketing consulting firm. Between 2003 and 2008, he authored five books on sales and marketing within the healthcare industry, showcasing his dedication to advancing the sector.

Glenn Cross

Independent Non-Executive Director and Chairman

With four decades in the life sciences sector, Glenn Cross has held senior executive roles across multinational and Australian companies. His expertise spans general management, sales, marketing, finance, distribution, and manufacturing. Notably, Glenn served as Chief Operating Officer and CEO of AusBiotech for over 13 years. Currently, he contributes as a non-executive director to various private and public companies, as well as investment funds.